Four leading Indian drug companies have received US Food and Drug Administration (USFDA) clearances in the last ten days for their manufacturing facilities, thus giving them an export boost.
The three plans situated in India which have received their establishment inspection report (EIR) from USFDA - belong to Lupin, Dr Reddy’s Laboratories and Strides Pharma.
Lupin’s manufacturing plant in Nagpur was inspected by the USFDA in January, “We are very happy to have received the EIR for our Nagpur facility, our largest and most advanced oral solid dosage facility”.
Dr Reddy’s Laboratories’ plant five at Miryalaguda in Telangana received the EIR, along with Strides Pharma’s Bengaluru plant capable of manufacturing dosage formulations like tablets, capsules, ointments, creams and liquids, and complex generics. Biocon’s insulin plant in Malaysia was also cleared by the USFDA.
India had recently approved the export of anti-malarial drug Hydroxychloroquine - touted as a prophylaxis against Covid-19, to the US. Analysts though have played down a link between the two events.
As you are no doubt aware, Swarajya is, all in all, a reader-subscription-backed business model and in order to make sure we build a media platform with only the best interests of India at heart, we need your backing.
And in challenging times like this, we need your support now more than ever—to continue bringing you stories that are often shrugged off.
For us to invest in quality reporting and continue bringing you the right stories, it takes a lot of time and money.
Partner with us, be a patron or a subscriber. We need your support, throughout.